Biolevate Raises €30M, Runs 100,000 Agents at Once

Biolevate, a Paris-based AI automation startup for regulated life sciences, raised €30 million in Series A funding and simultaneously opened a Boston office to expand into the U.S. pharmaceutical market, according to Tech.eu's reporting on the round. The round was co-led by RAISE France, the investment vehicle of French entrepreneur Aymar Hénin, and Orange Ventures, with participation from the MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures.

Biolevate has developed a hyperspecialised, enterprise-grade agentic platform that transforms complex scientific and regulatory knowledge into evidence-grade, auditable workflows, according to the company's own announcement of the round. Unlike general-purpose AI systems, the platform keeps outputs grounded in source evidence at every stage, letting life sciences organizations deploy AI confidently in regulated environments while preserving human oversight. Initially built to accelerate regulatory approval workflows specifically, the platform now spans the full life sciences value chain, including research, clinical trials, health technology assessments, regulatory dossiers, drug discovery, and drug development.

Biolevate's disclosed capabilities are notably concrete for a Series A-stage company. The company says its platform is capable of running 100,000 agents concurrently, and claims to accelerate systematic literature reviews and research synthesis by 16 times, while delivering an 80% efficiency gain in regulatory intelligence and compliance work, according to the company's own announcement.

Biolevate was founded in Paris by a team of former Dataiku engineers and AI researchers, according to Tech.eu's reporting, giving the founding team genuine enterprise AI platform experience directly relevant to building agentic systems capable of operating reliably within highly regulated environments.

Biolevate's growth claims are backed by genuinely concrete, disclosed metrics rather than purely theoretical potential. Since its 2024 seed round, the company has expanded its partnerships and customer base across the life sciences sector, now serving more than a dozen enterprise customers with annual recurring revenue growing 20-fold over the past year, according to The Next Web's reporting on the round. That trajectory places Biolevate alongside the broader wave of AI-driven life sciences investment we've tracked closely this year, including Faro AI's own $37.3 million raise for AI agents in clinical drug development.

Biolevate co-founder and CEO Joël Belafa connected the company's growth directly to its founding mission. "We started Biolevate with a mission-driven team united by the belief that AI could improve millions of lives if we empowered the right people and solved the right technological challenges. Today, our vision is becoming reality," Belafa said, according to Tech.eu's reporting. Newly appointed chairman Aymar Hénin framed the company's core challenge in similarly trust-focused terms: "Biolevate is addressing one of the most important challenges in life sciences: turning the extraordinary potential of AI into trusted, evidence-grade automation that can operate at scale in regulated environments." Orange's Jérôme Berger, who also joins the board as part of the deal, echoed that framing directly: "In healthcare, the value of AI depends on the trust people can place in the knowledge" it produces.

Biolevate's raise is worth understanding for any pharmaceutical or life sciences company evaluating AI automation specifically for regulatory and scientific workflows, since the company's specific emphasis on evidence-grounded, auditable outputs directly addresses the trust and compliance concerns that have historically slowed AI adoption in highly regulated healthcare environments.

For businesses tracking the broader life sciences AI investment landscape, Biolevate's expansion into Boston, positioning itself at the heart of the U.S. pharmaceutical industry, alongside disclosed partnerships with Sanofi, Nvidia, and Microsoft, signals genuine, credible enterprise traction worth watching as the company scales internationally.

What does Biolevate's AI platform actually do?
Biolevate builds an agentic AI platform that automates scientific and regulatory workflows across the life sciences value chain, including research, clinical trials, drug discovery, and regulatory submissions, keeping outputs grounded in source evidence for use in regulated environments.

How much funding has Biolevate raised?
Biolevate raised €30 million in Series A funding co-led by RAISE France and Orange Ventures, with participation from the MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures.

What results has Biolevate reported for its customers?
The company claims its platform can run 100,000 agents concurrently, accelerates systematic literature reviews by 16 times, and delivers an 80% efficiency gain in regulatory intelligence and compliance work, with annual recurring revenue growing 20-fold over the past year across more than a dozen enterprise customers.

Biolevate raised €30 million in Series A funding and opened a Boston office to expand into the U.S. pharmaceutical market, scaling its agentic AI platform that automates scientific and regulatory workflows across the life sciences industry while keeping outputs grounded in source evidence for regulated environments. The company, founded by former Dataiku engineers, claims its platform can run 100,000 agents simultaneously, accelerate literature reviews 16-fold, and deliver an 80% efficiency gain in regulatory compliance work, with annual recurring revenue growing 20-fold over the past year across more than a dozen enterprise customers including partnerships with Sanofi, Nvidia, and Microsoft.